An observational study in Cancer and Type 2 Diabetes, sponsored by Odense University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Odense University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to see how type 2 diabetes affects quality of life in cancer patients receiving immunotherapy. We want to know if patients with diabetes have a greater decline in quality of life over six months compared to those without. The main question we aim to answer is:
- How does quality of life change over six months in patients with versus without diabetes?
Participants will complete quality-of-life surveys at the start, then at 3 and 6 months. This will help us see if diabetes adds extra challenges during cancer treatment
Immune checkpoint inhibitors (ICIs) have transformed the management of multiple solid malignancies by improving survival and enabling durable disease control. By targeting inhibitory immune checkpoints such as PD-1, PD-L1, and CTLA-4, these therapies enhance anti-tumour immune responses. However, immune activation may also result in immune-related adverse events (irAEs), which can affect multiple organ systems and range from mild to life-threatening. As survival improves, long-term and chronic toxicities are increasingly recognised, highlighting the importance of patient-centred outcomes such as health-related quality of life (HRQoL).
Diabetes mellitus (DM) is a common comorbidity among patients with cancer and is associated with increased symptom burden, functional impairment, and reduced HRQoL. Type 2 diabetes (T2D) has also been associated with adverse cancer outcomes and may influence both the effectiveness and toxicity profile of systemic anticancer therapy, including ICIs. In addition, ICIs can induce immune-related diabetes mellitus (ir-DM), a rare but clinically significant form of new-onset insulin-dependent diabetes requiring lifelong insulin treatment. Despite its clinical relevance, the interaction between pre-existing diabetes, ICI therapy, and longitudinal HRQoL remains insufficiently characterised.
Although HRQoL is generally reported to remain stable during ICI therapy in unselected cancer populations, it is unknown whether similar patterns are observed in patients with pre-existing DM or in those who develop ir-DM during treatment. Given the metabolic, functional, and psychosocial burden associated with diabetes, this patient group may be particularly vulnerable to deterioration in HRQoL during immunotherapy.
The primary aim of this study is to compare longitudinal changes in HRQoL between patients with T2D and non-diabetic patients from baseline to 3 and 6 months after initiation of ICI therapy. The primary hypothesis is that patients with T2D will experience a greater decline in HRQoL over the first six months of treatment compared with non-diabetic patients.
This is a prospective, multicentre cohort study of adult cancer patients initiating ICI therapy. Data will be collected prospectively using a secure electronic case report form across participating centres.
At baseline, demographic characteristics, cancer type and stage, treatment intent and planned ICI regimen, diabetes status (no diabetes, type 1 diabetes, or type 2 diabetes), diabetes treatment status, performance status, and baseline patient-reported outcomes will be recorded.
During follow-up, data will be collected on ICI exposure, treatment discontinuation and reasons for discontinuation, immune-related adverse events, hospitalisations, disease progression, survival status, and the occurrence of immune-related diabetes mellitus.
Patient-reported outcomes will be assessed using the EORTC QLQ-C30 and EQ-5D-5L questionnaires in all participants, and the PAID questionnaire in participants with diabetes. Assessments will be performed at baseline and at 3 and 6 months after treatment initiation.
Immune-related diabetes mellitus will be defined as new-onset insulin-dependent diabetes occurring after initiation of ICI therapy and consistent with marked beta-cell failure, classified according to established international clinical recommendations.
This study will provide prospective real-world data on HRQoL trajectories and survival among cancer patients with and without diabetes receiving ICI therapy, and will estimate the incidence and clinical characteristics of immune-related diabetes mellitus in a nationwide setting.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 920 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with solid malignancies initiating immune checkpoint inhibitor therapy in routine clinical practice, with and without pre-existing type 2 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients have cancer and receive immunotherapy
The patients have cancer and receive immunotherapy
Change in EORTC QLQ-C30 Global Health Status score
Change in health-related quality of life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status scale. Scores range from 0 to 100, with higher scores indicating better global quality of life. The outcome compares changes from baseline between patients with type 2 diabetes and patients without diabetes receiving immune checkpoint inhibitor (ICI) therapy.
Time frame: Baseline, 3 months and 6 months
Change in EQ-5D-5L Index Value
Health status measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The index value is derived from the five EQ-5D dimensions using a population value set, where higher values indicate better health status.
Time frame: Baseline to 3 months and 6 months
Change in EQ-5D-5L Visual Analogue Scale (EQ-VAS) score
Self-rated health measured using the EQ-5D-5L visual analogue scale (EQ-VAS), where participants rate their health from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline, 3 months and 6 months
Incidence of immune-related diabetes mellitus
Incidence of immune-related diabetes mellitus within 12 months of ICI initiation (number and proportion). Record occurrence of diabetic ketoacidosis at immune-related diabetes mellitus onset.
Time frame: Within 12 months after initiation of ICI.
Hospital Admissions
Number and type of hospital admissions within 6 months of ICI initiation, categorized Immune-related adverse event related, diabetes-related, or other. Derived measures include time to first hospitalization and length of stay.
Time frame: Within 6 months after initiation of ICI therapy.
Time to Treatment Failure
Time from first dose of immune checkpoint inhibitor (ICI) therapy to permanent discontinuation of ICI therapy for any reason (including disease progression, toxicity, or other causes) or death, whichever occurs first.
Time frame: Within 6 months after initiation of immune checkpoint inhibitor therapy
Time to death from any cause (Overall Survival)
Overall survival defined as time from initiation of ICI therapy to death from any cause.
Time frame: Within 12 months after initiation of immune checkpoint inhibitor therapy
Association Between Clinical Events and HRQoL Outcomes
Exploratory analyses examining associations between clinical events (e.g., hospitalizations and immune-related adverse events) and changes in health-related quality of life measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores range from 0 to 100, with higher scores indicating better global health status and quality of life.
Time frame: Baseline to 6 months
Change in Problem Areas in Diabetes Score
Change in diabetes-related emotional distress measured by the Problem Areas in Diabetes (PAID) questionnaire. The PAID questionnaire assesses diabetes-specific emotional distress, with higher scores indicating greater distress. This outcome is assessed in participants with diabetes.
Time frame: Baseline to 6 months (assessed at baseline, 3 months, and 6 months)
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.
Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 18 months is below that.
Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.